The Vanderbilt-Meharry CFAR (CFAR) will build on existing strong interactions between these two complementary institutions (Vanderbilt University Medical Center and Meharry Medical College) in Nashville, Tennessee to develop improved infrastructure support, and to enhance the multidisciplinary, collaborative environment, for AIDS research. Innovative research will be promoted in all areas relevant to HIV epidemiology/prevention, pathogenesis, and treatment. Current strengths in translational and pathogenesis research will be bolstered, including building capacity to comprehensively study racial disparities relevant to HIV disease. The Vanderbilt-Meharry CFAR will function through 5 Cores: Administrative, Developmental, Clinical Discovery, Immunopathogenesis, and Virology. These Cores reflect the strengths in translational research in virus pathogenesis, immunobiology, and antiretroviral pharmacogenomics;a comprehensive clinical database/specimen archive;unique outcomes research collaborative strength in non-HIV-related areas as well as in HIV disease;and consistently-productive units of several national clinical trials networks CFAR will also support development of minority scientists, improve outreach to the community and education for biomedical trainees/scientists about AIDS research, and enhance international HIV research. Scientific programs will encourage new collaborative projects. The coordination, collaboration, and seeding resources provided by the Vanderbilt-Meharry CFAR will greatly accelerate expansion of AIDS research at these institutions.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
3P30AI054999-07S1
Application #
8072913
Study Section
Special Emphasis Panel (ZAI1-BDP-A (J1))
Program Officer
Namkung, Ann S
Project Start
2010-05-24
Project End
2011-04-30
Budget Start
2010-05-24
Budget End
2011-04-30
Support Year
7
Fiscal Year
2010
Total Cost
$364,297
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Liu, Qi; Li, Chun; Wanga, Valentine et al. (2018) Covariate-adjusted Spearman's rank correlation with probability-scale residuals. Biometrics 74:595-605
Li, Binglan; Verma, Shefali S; Veturi, Yogasudha C et al. (2018) Evaluation of PrediXcan for prioritizing GWAS associations and predicting gene expression. Pac Symp Biocomput 23:448-459
Anderegg, Nanina; Johnson, Leigh F; Zaniewski, Elizabeth et al. (2017) All-cause mortality in HIV-positive adults starting combination antiretroviral therapy: correcting for loss to follow-up. AIDS 31 Suppl 1:S31-S40
Fritz, Cristin Q; Blevins, Meridith; Lindegren, Mary Lou et al. (2017) Comprehensiveness of HIV care provided at global HIV treatment sites in the IeDEA consortium: 2009 and 2014. J Int AIDS Soc 20:20933
Verma, Anurag; Bradford, Yuki; Verma, Shefali S et al. (2017) Multiphenotype association study of patients randomized to initiate antiretroviral regimens in AIDS Clinical Trials Group protocol A5202. Pharmacogenet Genomics 27:101-111
Nicholas, Katherine J; Flaherty, David K; Smith, Rita M et al. (2017) Chronic HIV-1 Infection Impairs Superantigen-Induced Activation of Peripheral CD4+CXCR5+PD-1+ Cells, With Relative Preservation of Recall Antigen-Specific Responses. J Acquir Immune Defic Syndr 74:72-80
Drozd, Daniel R; Kitahata, Mari M; Althoff, Keri N et al. (2017) Increased Risk of Myocardial Infarction in HIV-Infected Individuals in North America Compared With the General Population. J Acquir Immune Defic Syndr 75:568-576
Muzaale, A D; Althoff, K N; Sperati, C J et al. (2017) Risk of End-Stage Renal Disease in HIV-Positive Potential Live Kidney Donors. Am J Transplant 17:1823-1832
Rebeiro, Peter F; Gange, Stephen J; Horberg, Michael A et al. (2016) Geographic Variations in Retention in Care among HIV-Infected Adults in the United States. PLoS One 11:e0146119
Pettit, April C; Mendes, Adell; Jenkins, Cathy et al. (2016) Timing of Antiretroviral Treatment, Immunovirologic Status, and TB Risk: Implications for Testing and Treatment. J Acquir Immune Defic Syndr 72:572-8

Showing the most recent 10 out of 203 publications